Choose your preferred way to stay informed of new case launches and settlement deadlines
Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027." Following this news, Skye's stock price fell over 8% on June 10, 2024.
In order to be eligible to join the SKYE class action lawsuit, you must have incurred a loss on shares of Skye purchased during the class period listed above.
TOP
